Suppr超能文献

相似文献

1
Profilin 1 is a potential biomarker for bladder cancer aggressiveness.
Mol Cell Proteomics. 2012 Apr;11(4):M111.009449. doi: 10.1074/mcp.M111.009449. Epub 2011 Dec 8.
2
IMAC fractionation in combination with LC-MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers.
J Proteome Res. 2013 Sep 6;12(9):3969-79. doi: 10.1021/pr400255h. Epub 2013 Aug 21.
3
LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
World J Urol. 2022 Oct;40(10):2387-2398. doi: 10.1007/s00345-022-04136-7. Epub 2022 Sep 4.
4
Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer.
Mol Cell Proteomics. 2015 Sep;14(9):2466-78. doi: 10.1074/mcp.M115.051524. Epub 2015 Jun 16.
6
Far from resolved: stromal cell-based iTRAQ research of muscle-invasive bladder cancer regarding heterogeneity.
Oncol Rep. 2014 Oct;32(4):1489-96. doi: 10.3892/or.2014.3340. Epub 2014 Jul 18.
7
Urinary markers in the everyday diagnosis of bladder cancer.
Urologia. 2013 Sep-Dec;80(4):265-75. doi: 10.5301/urologia.5000041. Epub 2013 Nov 29.
8
Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer.
Proteomics. 2012 Jan;12(1):135-44. doi: 10.1002/pmic.201000810. Epub 2011 Dec 2.

引用本文的文献

2
Recent progress in mass spectrometry-based urinary proteomics.
Clin Proteomics. 2024 Feb 22;21(1):14. doi: 10.1186/s12014-024-09462-z.
3
Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease.
Front Immunol. 2023 Dec 14;14:1239151. doi: 10.3389/fimmu.2023.1239151. eCollection 2023.
4
Association of PFN1 Gene Polymorphisms with Bone Mineral Density, Bone Turnover Markers, and Osteoporotic Fractures in Chinese Population.
Calcif Tissue Int. 2023 Aug;113(2):207-215. doi: 10.1007/s00223-023-01102-2. Epub 2023 Jul 4.
5
A simple urine test by 3D-plus-3D immunoassay guides precise cancer diagnosis.
Bioeng Transl Med. 2023 Jan 18;8(3):e10489. doi: 10.1002/btm2.10489. eCollection 2023 May.
8
Cathelicidin-3 Associated With Serum Extracellular Vesicles Enables Early Diagnosis of a Transmissible Cancer.
Front Immunol. 2022 Mar 29;13:858423. doi: 10.3389/fimmu.2022.858423. eCollection 2022.
9
Gene Polymorphisms and the Bone Mineral Density Response to Alendronate Therapy in Postmenopausal Chinese Women with Low Bone Mass.
Pharmgenomics Pers Med. 2021 Dec 23;14:1669-1678. doi: 10.2147/PGPM.S344818. eCollection 2021.
10
Mutations in Profilin 1 Cause Early-Onset Paget's Disease of Bone With Giant Cell Tumors.
J Bone Miner Res. 2021 Jun;36(6):1088-1103. doi: 10.1002/jbmr.4275. Epub 2021 Mar 10.

本文引用的文献

1
Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.
Curr Opin Urol. 2011 Sep;21(5):420-7. doi: 10.1097/MOU.0b013e32834956d6.
2
Immunohistochemical biomarkers for bladder cancer prognosis.
Int J Urol. 2011 Sep;18(9):616-29. doi: 10.1111/j.1442-2042.2011.02809.x. Epub 2011 Jul 20.
4
Comprehensive human urine standards for comparability and standardization in clinical proteome analysis.
Proteomics Clin Appl. 2010 Apr;4(4):464-78. doi: 10.1002/prca.200900189. Epub 2010 Feb 3.
5
Secretome-based proteomics reveals sulindac-modulated proteins released from colon cancer cells.
Proteomics Clin Appl. 2009 Apr;3(4):433-51. doi: 10.1002/prca.200800077. Epub 2009 Jan 8.
7
Neutrophil serine proteases: mediators of innate immune responses.
Curr Opin Hematol. 2011 Jan;18(1):19-24. doi: 10.1097/MOH.0b013e32834115d1.
8
9
Secretome proteomics for discovery of cancer biomarkers.
J Proteomics. 2010 Nov 10;73(12):2291-305. doi: 10.1016/j.jprot.2010.07.001. Epub 2010 Jul 15.
10
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer.
Urol Oncol. 2010 Jul-Aug;28(4):441-8. doi: 10.1016/j.urolonc.2009.11.004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验